acp-196 and Ecchymosis

acp-196 has been researched along with Ecchymosis* in 2 studies

Reviews

1 review(s) available for acp-196 and Ecchymosis

ArticleYear
Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.
    American journal of clinical dermatology, 2020, Volume: 21, Issue:6

    The development of Bruton's tyrosine kinase (BTK) inhibitors represents a major breakthrough in the treatment of chronic lymphocytic leukemia and other B cell malignancies. The first-generation inhibitor ibrutinib works by covalent irreversible binding to BTK, a non-receptor tyrosine kinase of the TEC (transient erythroblastopenia of childhood) family that plays a critical role in the B-cell receptor signaling pathway. It also induces an 'off-target' inhibition of a range of other kinases including (but not limited to) epidermal growth factor receptor (EGFR), SRC, and other kinases of the TEC family (interleukin-2-inducible T-cell kinase [ITK], Tec, BMX). Dermatological toxicities are among the most common toxicities of ibrutinib, but remain of mild to moderate intensity in most cases and are readily manageable. Their incidence is highest during the first year of treatment and declines over time. In addition, it has been postulated that ibrutinib-related dermatologic adverse events are mediated by the direct binding to both BTK and other 'off-target' kinases. Bruising, ecchymoses, and petechiae represent the most characteristic dermatologic adverse events. Nail and hair changes are also common, as skin infections (opportunistic infections including herpes simplex and herpes zoster virus reactivations, and Staphylococcus aureus superinfection), folliculitis, and other types of rashes. Panniculitis, aphthous-like ulcerations with stomatitis, neutrophilic dermatosis, peripheral edema, and skin cracking can also occur. Next-generation BTK inhibitors, acalabrutinib and zanubrutinib, have been designed to optimize BTK inhibition and minimize off-target inhibition of alternative kinases (Tec, ITK, EGFR, SRC-family kinases). These drugs have been recently FDA-approved for relapsed or refractory mantle cell lymphoma. Although the overall incidence of their toxicities is expected to be more limited, acalubrutinib and zanubrutinib are associated with a range of dermatologic toxic effects that appear to be similar to those previously described with ibrutinib, including bruising and ecchymoses, panniculitis, human herpesvirus infections, cellulitis, and skin rash. In particular, both drugs induce skin bleeding events in more than 30% of patients treated. However, the available dermatological data are still rather limited and will have to be consolidated prospectively. This review article analyses the wide spectrum of dermatological toxicities that can be encountered w

    Topics: Adenine; Administration, Cutaneous; Agammaglobulinaemia Tyrosine Kinase; Benzamides; Biopsy; Drug Eruptions; Ecchymosis; Emollients; Humans; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Necrosis; Patient Education as Topic; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Antigen, B-Cell; Severity of Illness Index; Signal Transduction; Skin; Skin Care

2020

Other Studies

1 other study(ies) available for acp-196 and Ecchymosis

ArticleYear
Images in Vascular Medicine. Rumpel-Leede phenomenon in a patient with chronic lymphocytic leukemia treated with acalabrutinib.
    Vascular medicine (London, England), 2020, Volume: 25, Issue:3

    Topics: Agammaglobulinaemia Tyrosine Kinase; Aged, 80 and over; Antineoplastic Agents; Benzamides; Capillary Fragility; Chronic Disease; Ecchymosis; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Protein Kinase Inhibitors; Pyrazines; Risk Factors; Stockings, Compression; Treatment Outcome; Venous Insufficiency

2020